This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Garofoli, PharmD, BCACP, CTTS, FAPhA Publication Article Drug Topics Journal Drug Topics May/June 2025 Volume 169 Issue 03 Pharmacy team members can help patients prepare for upcoming travels, ensuring they are up to date with the recommended vaccines for their locations. The first resource is the CDC’s Yellow Book.
AC Immune SA has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy vaccine candidate for Alzheimer’s disease. The anti-Abeta therapy “specifically targets the most toxic forms of Abeta” according to Dr Andrea Pfeifer, CEO of AC Immune SA.
RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.
Moderna has announced that its cancer vaccine mRNA-4157/V940 along with Keytruda secured the European Medicines Agency (EMA) Priority Medicines (PRIME) scheme designation for the adjuvant treatment of high-risk stage III/IV melanoma patients after complete resection.
Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science officer respectively of Transgene, to discuss cancer vaccines in general and Transgene’s recent work in the space in particular. . Tune in to learn more. . You can listen to episode 58 of the? Podbean. .
Are you finally thinking of starting a vaccine program in your independent pharmacy? Adding vaccine administration to your list of pharmacy services is a great way to serve and protect your community while increasing your pharmacy’s visibility, revenue, and profit. Additional revenue Vaccinations can be a profitable service.
After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).
Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.
She hesitated, and I took her into our immunization room. She admitted she was using them for injection drug use, and I gave her 5 syringes we were using for COVID-19 vaccine injections that were provided by the government. To read these stories and more, download the PDF of the Drug Topics May/June issue here.
To read these stories and more, download the PDF of the Drug Topics May/June issue here. Related Content Measles Outbreak Reaches Over 800 Confirmed Cases in the US Ashley Gallagher June 7th 2025 Article Building trust with patients through fact-based information could help boost vaccination rates to the desirable coverage.
9 In response to the fires in Los Angeles County in January 2025, a 10-year study, called the Los Angeles Fire Human Exposure and Long-Term Health Study, was launched to assess the long-term effects of wildfire smoke exposure, including respiratory, cardiovascular, neurological, reproductive, and immune system impacts. January 31, 2025.
link] Tichy EM, Hoffman JM, Tadrous M, et al. National trends in prescription drug expenditures and projections for 2024. Am J Health Syst Pharm. 2024;81(14):583-598.
LinkedIn Workplace Learning Report 2024. LinkedIn Learning. Accessed May 15, 2025. link] The views expressed in this article are the authors' own and do not reflect the views of their employer.
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Addressing pharmacy deserts and enhancing interdisciplinary collaboration, especially with social workers, are crucial for improving health care access.
HOPA has selected 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. Additional information is available here.
Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.
Download Issue PDF Download RIS Articles in this issue Evaluation of a Pharmacy-Delivered Oncofertility Intervention Pharmacy Leadership in the Future of Oncology Care Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
HOPA has selected 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. Additional information is available here.
Results Data will include toxicity management in the OP setting (eg, rates and grades of CRS/immune effector cell–associated neurotoxicity syndrome, deferred admissions, etc), an algorithm for appropriately selecting patients for OP administration, and a specific OP SUD treatment protocol.
HOPA has selected 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. Additional information is available here.
doi:10.5688/ajpe8920 Download Issue PDF Download RIS Articles in this issue Walgreens Launches Program to Enable Technicians to Pursue Pharmacy School Pharmacists Can Provide Travel Health Tips for Patients Is Fluoride Friend or Foe? Chesnut R, Anderson GW, Buncher O, Dietrich MA, Rosenberg JM, Ross LJ. Am J Pharm Educ.
REFERENCE Soefje SA. 505(b)(2) drugs: new chaos for infusion centers. Presented at: Hematology/Oncology Pharmacy Association 2025 Annual Conference; April 9-12, 2025; Portland, OR.
Accessed January 20, 2025. link] Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacol Sci. 2024;45(5):406-418. doi:10.1016/j.tips.2024.03.004
HOPA has selected 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. Additional information is available here.
RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.
Submit Download Issue PDF Download RIS Articles in this issue Spring 2025 Quiz: Test Your Pharmacy Knowledge! Image credit: Orawan | stock.adobe.com Which of the following drug classes is included in the Expert Consensus Decision Pathway guideline–directed medical therapy for heart failure?
After a long period of inactivity in RSV vaccine development , two pharmaceutical companies are now approaching regulatory decisions for their RSV vaccines. Both Pfizer and GSK have major approval decisions regarding the use of their RSV vaccines for older adults this May. What incentivises a country to cover a vaccine?
HOPA has selected 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. Additional information is available here.
HOPA has selected 4.0 CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. Additional information is available here.
Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Please check your inbox to download the Whitepaper. Data Insights The gold standard of business intelligence.
link] Download Issue PDF Download RIS Articles in this issue Is Fluoride Friend or Foe? FDA begins action to remove ingestible fluoride prescription drug products for children from the market. News release. May 13, 2025. Accessed May 15, 2025.
The plaintiffs were awarded attorney’s fees, expenses, and service costs, and the settlement agreement includes a fund of $1.075 million, with a cap of $5000 per class member. REFERENCE Webb v Injured Workers Pharmacy, LLC, 1:22-cv-10797-RGS (ED Mass 2022).
You can even download additional resources and graphics related to national diabetes day at this link. Promote Routine Immunizations People with diabetes are at a higher risk of complications from infections.
World Immunization Week: April 24-30. National Immunization Awareness Month. National Influenza Vaccination Week: December 6-12. Cervical Health Awareness Month | S hare downloadable content from the NCCC and advocate for HPV vaccinations. National Cancer Prevention Month. National Kidney Month. UV Safety Month.
Source: GlobalData Pharmaceutical Intelligence Center Clinical trial catalysts In late January, AC Immune released positive interim results from the Phase I/II trial (NCT05462106) studying the company’s vaccine in patients with prodromal Alzheimer’s disease. Please check your email to download the Report.
A clinical-stage biopharmaceutical firm, Liminatus focuses on the development of new therapies for cancer that utilises the immune system of the body to detect and fight cancer cells. The GCC Vaccine is being analysed in Phase II clinical trials. The boards of directors of both companies have granted approval for the merger.
Similarly, while some nanoscale delivery systems can exhibit prolonged lifetimes in the bloodstream, others have short circulation times or can be viewed as foreign materials by the immune system and rapidly cleared. All these challenges tend to lead to high costs for therapeutics and vaccines leveraging nanoscale drug delivery systems.
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response. . Download the full event guide to find out more.
With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub. With an initial focus on enchaining mRNA technology and developing a vaccine for Chlamydia, the research at the hub is anticipated to commence in the first quarter of next year.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content